Journal of the Korean Ophthalmological Society 1989;30(2):253-259.
Published online February 1, 1989.
The Effects of 1% Apraclonidine(Iopidine) on Intraocular Pressure in Normal Persons.
Young Joo Shin, Hai Ryun Jung
Depatement of Ophthalmolgy, College of Medicine, Korea University, Seoul, Korea.
정상인에서 1% Apraclonidine ( Iopidine ) 의 안압 하강 효과
신영주(Young Joo Shin),정해륜(Hai Ryun Jung)
Abstract
Apraclonidine(Iopidine, p-aminoclonidine hydrochloride, ALO 2145) is a peripheral alpha 2 agonist. We evaluated the effect of apraclonidine on IOP and its systemic or ocular side effects in normal subjects. We measured IOP, BP(systolic and diastolic), pulse rate, pupillary size, palpebral fissure width and checked the ocular side effects, such as conjunctival blanching, irritation, and headache, etc. Mean IOP of eyes instilled with 1% apraclonidine fell by 20 +/- 8.5%, from 15.5 +/- 3.9mmHg to 12.4 +/- 2.6 mmHg, 3 hours after instillation. The effect remained up to 7 hours after instillation(p<0.01). Mean IOP of the fellow eyes did not show statistically significant difference, compared with the baseline; but when compared with the placebo group, there was a slight but statistically significant difference(p<0.01) from 3 hours to 7 hours after instillation. There was no significant difference between the eyes instilled with 1% apraclonidine and the placebo in terms of the mean systolic and diastolic BP, pulse rate, pupillary size and palpebral fissure width. Conjunctival blanching was noted in 51.6% of the eyes instilled with 1% apraclonidine. Other side effects noted were headache(25.8%), lid elevation sense(16.1%), lid drooping sense of the fellow eye(6.4%), nausea(9.7%), and irritation(3.2%).
Key Words: apraclonidine;para-arninoclonidine;iopidine;intraocular pressure;glaucoma;side effect


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next